ArticleHepatology communications2022

Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.

Archana Vijayakumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.